Profile - To The Moon

Simm

Posts · 25Posts · 25
Following · 0Following · 0
Followers · 0Followers · 0

- SimmSimm
  ·2024-06-10
  Share your opinion about this news…
  3 Reasons to Buy Palantir Stock (and 1 Reason to Avoid It)
  Palantir's latest AI product has been a game changer for the company.
  3 Reasons to Buy Palantir Stock (and 1 Reason to Avoid It)
  220 Comment
  Like
  Share
  Report
- SimmSimm
  ·2022-05-20
  Bla bka bla bla...but life must go on, hold steady and continue to have faith
  Palantir: Complete Disaster
  So, Palantir Technologies Inc. (NYSE:PLTR) stock has been a total disaster for longs. Many retail "b
  Palantir: Complete Disaster
  534 Comment
  3
  Share
  Report
- SimmSimm
  ·2021-08-04
  Will the booster jab (3rd jab vaccination) boost the share ptocebof PFE ?
  Pfizer hikes 2021 outlook after vaccine boosts sales, profit
  Strong sales of its COVID-19 vaccine and other drugs helped Pfizer nearly double its second-quarter
  Pfizer hikes 2021 outlook after vaccine boosts sales, profit
  765 1
  4
  Share
  Report
- SimmSimm
  ·2021-08-04
  Turn to RED MOON now!
  506 Comment
  Like
  Share
  Report
- SimmSimm
  ·2021-08-04
  Toyota! My trusted car
  Sorry, this post has been deleted
  602 1
  4
  Share
  Report
- SimmSimm
  ·2021-08-04
  Inari has good prospect! At 18x is a good bargain
  3 COVID Stocks That Could Soar Higher
  Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021. Key Points Pfi
  3 COVID Stocks That Could Soar Higher
  802 2
  9
  Share
  Report
- SimmSimm
  ·2021-07-28
  Anyone drinking beers
  429 Comment
  1
  Share
  Report
- SimmSimm
  ·2021-07-27
  Nice beer, Samual Adam
  551 Comment
  Like
  Share
  Report
- SimmSimm
  ·2021-07-21
  ???
  奈雪的茶跌近4% 较招股价已跌超35%
  7月21日消息，奈雪的茶持续下跌，现跌3.82%，报13.08港元，最新市值224.34亿港元。　　奈雪的茶于6月30日首挂上市，每股定价19.8港元。上市当日破发，此后股价持续下行，今日再度跌近4%，低见12.86港元，较招股价已跌超35%。海量资讯、精准解读，尽在新浪财经APP
  奈雪的茶跌近4% 较招股价已跌超35%
  871 Comment
  1
  Share
  Report
- SimmSimm
  ·2021-07-21
  What about Nio; Xpeng Lucid etc etc ?
  Sorry, this post has been deleted
  566 Comment
  6
  Share
  Report
No following yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3574328305423311","uuid":"3574328305423311","gmtCreate":1611235097167,"gmtModify":1620450783533,"name":"Simm","pinyin":"simm","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":91,"tweetSize":25,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":1,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":2,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.10.18","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":4,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":315223422099496,"gmtCreate":1717990269853,"gmtModify":1717990271913,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574328305423311","authorIdStr":"3574328305423311"},"themes":[],"htmlText":"Share your opinion about this news…","listText":"Share your opinion about this news…","text":"Share your opinion about this news…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/315223422099496","repostId":"2441307342","repostType":2,"repost":{"id":"2441307342","kind":"highlight","pubTimestamp":1717988788,"share":"https://ttm.financial/m/news/2441307342?lang=&edition=fundamental","pubTime":"2024-06-10 11:06","market":"us","language":"en","title":"3 Reasons to Buy Palantir Stock (and 1 Reason to Avoid It)","url":"https://stock-news.laohu8.com/highlight/detail?id=2441307342","media":"Motley Fool","summary":"Palantir's latest AI product has been a game changer for the company.","content":"<html><head></head><body><ul style=\"\"><li><p>Palantir&#39;s revenue growth accelerated, thanks to AIP.</p></li><li><p>Management steadily guided for its profit margins to increase.</p></li><li><p>However, the stock is expensive for its growth rate.</p></li></ul><p>In the realm of artificial intelligence (AI) software, Palantir Technologies sticks out from the rest. Palantir has been in the AI business since its founding in 2003. Originally created to assist governments in processing data to deliver actionable insights, it has since expanded into the public sector, opening up a new business avenue.</p><p>With Palantir&#39;s multiple decades of expertise, it&#39;s becoming a top pick for companies looking to integrate AI models and decision-making into their businesses. Investors are noticing that momentum, piling into the stock as a result.</p><p>I agree that Palantir is a top AI pick, and I have three reasons why it&#39;s a buy. But I have one reason to avoid the stock, and it may trump the rest.</p><h2 id=\"id_1590136905\">Reason to buy 1: Palantir&#39;s latest product has been a hit</h2><p>While some of Palantir&#39;s AI tools have been around for a while, its latest product, Artificial Intelligence Platform (AIP), has been all the rage. While AIP probably could have used a better name (Palantir&#39;s other products sport cooler names like Foundry, Gotham, and Apollo), it gets the point across for what it does.</p><p>AIP gives clients the tools they need to integrate AI into everyday workflows. By centralizing all data flows into one location, AIP helps businesses make decisions on the most up-to-date information they have. It also allows large language model integration (the technology behind generative AI), which further arms users to automate and streamline workflows.</p><p>Palantir&#39;s management consistently used the word &#34;unprecedented&#34; when discussing AIP demand, and this platform will be a major revenue driver for years to come.</p><h2 id=\"id_3457250373\">Reason to buy 2: Revenue growth is accelerating</h2><p>Due to the &#34;unprecedented&#34; demand, Palantir&#39;s revenue growth has been accelerating. In Q1, revenue grew at a 21% clip to $634 million, the fastest pace since late 2022.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/398901b69af0a0d6cedf1e6549522e0d\" tg-width=\"720\" tg-height=\"441\"/></p><p>PLTR Revenue (Quarterly YoY Growth) data by YCharts</p><p>But Palantir isn&#39;t stopping there. In Q2, management expects revenue of $651 million, indicating 22% revenue growth. Growth acceleration is something investors love to see, and its quicker growth rates help justify the stock price.</p><p>Still, Palantir isn&#39;t just a growth-at-all-costs company.</p><h2 id=\"id_1319693756\">Reason to buy 3: Palantir&#39;s margins continue to improve</h2><p>Palantir flipped the profitability switch in 2023 when it started producing small profits. Since then, its profit margins have continued to steadily tick up, which can be an incredibly powerful combination when revenue growth is also accelerating.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/0a76b561140032c2fb8f417ebc677628\" tg-width=\"720\" tg-height=\"441\"/></p><p>PLTR Profit Margin (Quarterly) data by YCharts</p><p>Palantir&#39;s management understands that investors want to see profits eventually, so it is aligning business results with shareholder expectations. </p><h2 id=\"id_4137751275\">Reason to avoid: Palantir&#39;s stock is far from cheap</h2><p>Palantir checks all the boxes from a business outlook and financial standpoint, but there&#39;s still one more factor to consider: its price tag.</p><p>Even if everything about a stock is perfect, buying it at the wrong price can be a disaster. For example, <strong><a href=\"https://laohu8.com/S/ZM\">Zoom</a> Video Communications</strong> was a no-brainer stock during the pandemic. It had unbelievable growth, strong profits, and an incredible outlook, but anyone who bought at elevated levels in late 2020 is down nearly 90% from their initial investment.</p><p>Palantir&#39;s stock hasn&#39;t reached near the hubris as Zoom Video&#39;s did, but it&#39;s still valued at a hefty premium.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/3cb97bd6ab11a774071bcb94f5fa4077\" tg-width=\"720\" tg-height=\"441\"/></p><p>PLTR PS Ratio data by YCharts</p><p>At 21 times sales, its price-to-sales (P/S) ratio is nearly equal to its growth rate. This normally doesn&#39;t bode well for a stock, as it indicates incredibly high growth expectations.</p><p>But is that enough to completely avoid the stock? I don&#39;t think so. If investors avoided companies like <strong>Amazon </strong>or <strong>Nvidia </strong>because they were too expensive, they&#39;d have missed out on massive winners. However, highly priced stocks can be volatile, so you&#39;ll need to set a longer holding period of around five years to make it worth it.</p><p>If you can do that, then Palantir could be a fantastic AI investment at these levels.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Reasons to Buy Palantir Stock (and 1 Reason to Avoid It)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Reasons to Buy Palantir Stock (and 1 Reason to Avoid It)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-10 11:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2024/06/08/3-reasons-to-buy-palantir-stock-and-1-reason-to-av/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Palantir's revenue growth accelerated, thanks to AIP.Management steadily guided for its profit margins to increase.However, the stock is expensive for its growth rate.In the realm of artificial ...</p>\n\n<a href=\"https://www.fool.com/investing/2024/06/08/3-reasons-to-buy-palantir-stock-and-1-reason-to-av/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2024/06/08/3-reasons-to-buy-palantir-stock-and-1-reason-to-av/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2441307342","content_text":"Palantir's revenue growth accelerated, thanks to AIP.Management steadily guided for its profit margins to increase.However, the stock is expensive for its growth rate.In the realm of artificial intelligence (AI) software, Palantir Technologies sticks out from the rest. Palantir has been in the AI business since its founding in 2003. Originally created to assist governments in processing data to deliver actionable insights, it has since expanded into the public sector, opening up a new business avenue.With Palantir's multiple decades of expertise, it's becoming a top pick for companies looking to integrate AI models and decision-making into their businesses. Investors are noticing that momentum, piling into the stock as a result.I agree that Palantir is a top AI pick, and I have three reasons why it's a buy. But I have one reason to avoid the stock, and it may trump the rest.Reason to buy 1: Palantir's latest product has been a hitWhile some of Palantir's AI tools have been around for a while, its latest product, Artificial Intelligence Platform (AIP), has been all the rage. While AIP probably could have used a better name (Palantir's other products sport cooler names like Foundry, Gotham, and Apollo), it gets the point across for what it does.AIP gives clients the tools they need to integrate AI into everyday workflows. By centralizing all data flows into one location, AIP helps businesses make decisions on the most up-to-date information they have. It also allows large language model integration (the technology behind generative AI), which further arms users to automate and streamline workflows.Palantir's management consistently used the word \"unprecedented\" when discussing AIP demand, and this platform will be a major revenue driver for years to come.Reason to buy 2: Revenue growth is acceleratingDue to the \"unprecedented\" demand, Palantir's revenue growth has been accelerating. In Q1, revenue grew at a 21% clip to $634 million, the fastest pace since late 2022.PLTR Revenue (Quarterly YoY Growth) data by YChartsBut Palantir isn't stopping there. In Q2, management expects revenue of $651 million, indicating 22% revenue growth. Growth acceleration is something investors love to see, and its quicker growth rates help justify the stock price.Still, Palantir isn't just a growth-at-all-costs company.Reason to buy 3: Palantir's margins continue to improvePalantir flipped the profitability switch in 2023 when it started producing small profits. Since then, its profit margins have continued to steadily tick up, which can be an incredibly powerful combination when revenue growth is also accelerating.PLTR Profit Margin (Quarterly) data by YChartsPalantir's management understands that investors want to see profits eventually, so it is aligning business results with shareholder expectations. Reason to avoid: Palantir's stock is far from cheapPalantir checks all the boxes from a business outlook and financial standpoint, but there's still one more factor to consider: its price tag.Even if everything about a stock is perfect, buying it at the wrong price can be a disaster. For example, Zoom Video Communications was a no-brainer stock during the pandemic. It had unbelievable growth, strong profits, and an incredible outlook, but anyone who bought at elevated levels in late 2020 is down nearly 90% from their initial investment.Palantir's stock hasn't reached near the hubris as Zoom Video's did, but it's still valued at a hefty premium.PLTR PS Ratio data by YChartsAt 21 times sales, its price-to-sales (P/S) ratio is nearly equal to its growth rate. This normally doesn't bode well for a stock, as it indicates incredibly high growth expectations.But is that enough to completely avoid the stock? I don't think so. If investors avoided companies like Amazon or Nvidia because they were too expensive, they'd have missed out on massive winners. However, highly priced stocks can be volatile, so you'll need to set a longer holding period of around five years to make it worth it.If you can do that, then Palantir could be a fantastic AI investment at these levels.","news_type":1},"isVote":1,"tweetType":1,"viewCount":220,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9021630595,"gmtCreate":1653040550717,"gmtModify":1676535213137,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574328305423311","authorIdStr":"3574328305423311"},"themes":[],"htmlText":"Bla bka bla bla...but life must go on, hold steady and continue to have faith","listText":"Bla bka bla bla...but life must go on, hold steady and continue to have faith","text":"Bla bka bla bla...but life must go on, hold steady and continue to have faith","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9021630595","repostId":"2236030678","repostType":2,"repost":{"id":"2236030678","kind":"highlight","pubTimestamp":1653036810,"share":"https://ttm.financial/m/news/2236030678?lang=&edition=fundamental","pubTime":"2022-05-20 16:53","market":"us","language":"en","title":"Palantir: Complete Disaster","url":"https://stock-news.laohu8.com/highlight/detail?id=2236030678","media":"Seeking Alpha","summary":"So, Palantir Technologies Inc. (NYSE:PLTR) stock has been a total disaster for longs. Many retail \"b","content":"<html><head></head><body><p>So, <a href=\"https://laohu8.com/S/PLTR\">Palantir Technologies Inc.</a> (NYSE:PLTR) stock has been a total disaster for longs. Many retail &#34;bag-holders&#34; out there. And we would like to point out that we were wrong in our last column on the stock, despite making our members money. In our last column we predicted it would be emerging from the ashes and put out a profitable short-term trade recommendation in that piece. Winning.</p><p>However, <i>we were also wrong</i>, because we thought the bottom was put in after it reset back to trade just about at its direct public offering price. <i>We got that part wrong</i>.</p><p>While we get the win on the trade, we recognize that investors are getting creamed. Unfortunately this is a trader&#39;s market right now, and we have had a short bias the last few months, with selective long-term plays only in the most quality of names. We hate to see investors lose money, and we know it can be painful. The question is, what can we expect going forward. Is all hope lost here? We keep hearing that that technology stocks, especially those that are potential game-changing names, are on sale. But are they?</p><p>Names like Palantir are indeed often extremely expensive in the early stages. You really cannot value them on an earnings basis because there are no or very little earnings. Palantir also has a massive dilution problem, which means consistent positive EPS gets kicked further down the road. We think Palantir has a lot of potential, but this market is beyond unforgiving to those companies that do not make money or have sky high valuations. It does not matter at all how much promise they have; the stocks are all down and down massively. What can you do? We think there are three possible courses of action in the disaster that has been Palantir, all of which are correct.</p><p>The first option is the easiest, and perhaps a &#34;cop out&#34; for lack of a better term. But that option is to simply avoid the stock altogether in favor of deep value names offering some yield protection and are still managing to grow. We would not short down here at $7-$8, as the stock really has been pounded. The risk-reward is not favorable on a short after all of the action. So, you could do nothing and just watch it. If you own the stock, that would be a simple hold then. You could consider selling some upside calls on big bounces to lower cost basis if you choose.</p><p>The second course of action is in our wheelhouse. And that is to trade the name. Right now, we think that $7 level is a buy for gains to be sold at $8-$9, maybe $10. But this market environment is not going to get any better for innovative tech in the near-term. You could then consider some put options or mild shorts if the stock does enjoy a sizable bounce from the oversold conditions.</p><p>The third option is likely where a lot of readers are interested, and that is simply invest in the name, not obsess over the day-to-day tick in price. Add selectively to a well-rounded portfolio to improve cost basis, and put faith in management that it can deliver on growing the business profitably without diluting shareholders into oblivion. Right now this is a tall order for this company and management. While operationally the company is growing sufficiently, management has some credibility issues. What <a href=\"https://laohu8.com/S/AONE.U\">one</a> has to do is determine if what the company offers will solve enough headaches for customers that eventually the growing sales turn into sustained and growing profits.</p><p>For years, Palantir may lose money or breakeven. Of course, the theory goes that companies like this will lose money as they spend to attract customers and build their moat. They invest heavily in their growth while seeing revenues increase dramatically. And as we know, Palantir is seeing revenues grow tremendously.</p><p>So, what is our take? We think you wait for the next down day in the stock. It has enjoyed a sizable relief bounce from the lows, but we believe the stock will retest these lows as the economy continues to worsen, rates are going up, and markets struggle. We would be both traders and investors at $7. The risk could be that Palantir&#39;s growth fades and the company never really transforms the world. New competitors could emerge. Dilution could continue so long that positive EPS becomes out of reach without future buybacks. We hate to say it but frankly, it is not uncommon for stocks in seemingly innovative companies to wither away to sub $1 then eventually delist because the company failed to grow and deliver on its plans.</p><p>Although we were wrong in that bottom call, operationally we are seeing some positive signs. Internal metrics improve year-after-year for Palantir and we see no reason why the ongoing growth will not eventually lead to real profits, other than dilution. We admit and accept that so many great companies start out losing money. While the Russia/Ukraine conflict was a seemingly bullish development as it highlights a need to mine data for intelligence, some see a limited benefit for Palantir. For the long-term investor, we like a buy in this stock on weakness that sends the stock lower. While it will still be expensive, even for high growth tech, it will be much more reasonable compared to a few months ago. And it is not like the company is bleeding out and losing money hand over first. Palantir is breaking even and making some money some quarters.</p><h2>Palantir&#39;s Government and Commercial sectors showing growth</h2><p>In the just reported quarter, performance was strong on the top line and ahead of consensus estimates. Total revenue grew 31% year-over-year to $446 million, beating estimates by almost $3 million. However, its profitability was lower than expected by $0.02, and worse, guidance was less than consensus. That crushed the stock. But that said, both segments are doing well.</p><p>Palantir has two reporting segments: both the government and commercial segments. The commercial revenue stream continues to grow rapidly, while government results are likely to get a big boost following international strife. While the war in Ukraine may or may not lead to more business the company has invested in itself to grow sales. There are some concerns with backlog, but as we previously covered, Palantir has been hiring.</p><p>Palantir has expanded its sales team and they have been working to secure new orders. However, the Government revenues have slowed their growth somewhat. Deceleration of revenue growth is definitely a negative for a company like this that does not enjoy high earnings. They rose 16% from last year, and the company added a total of 40 net new customers in the quarter, which is very positive, 3 on the government side and 37 on the commercial side. We think it is important to note that the commercial space is doing well. The commercial revenue is expanding rapidly, increasing 132% in 2021, and here in Q1, it rose 54% year-over-year.</p><p>Palantir is seeing very positive momentum in its margins as well. Positive movement in margins is important in a software company as it really highlights strengths, or weaknesses, in the way it distributes its products. Palantir is delivering. Adjusted gross margin was 81%. Contribution margin was 57%. First quarter adjusted income from operations, excluding stock-based compensation and related employer payroll taxes was $117 million, representing an adjusted operating margin of 26%, ahead of management&#39;s prior guidance of 23%. This is positive.</p><h2>Palantir is slightly profitable, for now</h2><p>Despite the pull back now to single-digits, the stock is actually still expensive, like so many other growth tech names. The company lost $39 million in the quarter operationally, but adjusted income from operations was $117 million. The company is still free cash flow positive. Adjusted free cash flow was $30 million for the quarter. That said, the company was profitable at a $0.02 adjusted EPS bottom line figure, but this missed estimated by $0.02, so that is a negative, and another reason the stock is down.</p><p>We say the company is profitable for now for two reasons. First, there is a ton of stock based-compensation. This has been discussed in the past but we have to reiterate that we like that management has acknowledged that it is a problem. Still, it is ongoing, and every share that is issued waters down the ability to increase EPS. In short, shareholders could be diluted into losses. The second reason is that although there is growth internationally, as well as big gains in the U.S., we could see the government and companies slash spending if there is a recession. Each week, things seem to get worse in terms of how expensive things are, and corporate earnings reports continue to highlight the tremendous pressure inflation is putting on them. While Palantir&#39;s technology should help governments and businesses alike operate more efficiently, and therefore more profitably, we could see reduced spending on services like this.</p><h2>Still expensive</h2><p>On the valuation front, the stock is still pricey. Sure, looking at traditional price-to-earnings is futile, but if you did you would see a stock at like 50X. Very pricey. Perhaps the more appropriate measure is the price-to-sales ratio, but not only is this still very high, the market has basically said it is no longer willing to pay for sky high multiples. Keep that in mind. At 9X sales, the stock is much cheaper than it has ever been, but it is still not &#34;cheap&#34;. We would highlight that the PEG ratio is reasonable and we like the cash flow metrics.</p><h2>The outlook is murky</h2><p>The biggest concern right now is not valuation. It is not dilution. It is not the &#34;overall market.&#34; The largest issue is a slowdown in performance. The Q2 guidance was pretty weak. The company perhaps is underpromising to overdeliver, by management guided to a base case of $470 million in revenue. This was below consensus of $484 million. However in the release management noted that &#34;there is a wide range of potential upside to [the] guidance.&#34; The one positive factor to highlight is that Palantir continues to see 30% annual revenue growth through 2025.</p><h2>Take home</h2><p>The company operates with no debt and has nice positive free cash flow. They are poised to benefit from strong secular trends in big data and using analytics to improve operations. In the short-term, it is painful. Long-term, minus the dilution issues, there is a lot of promise here for future profits. The customer growth is impressive as is the revenue growth. While the stock has been a disaster, man analysts have price targets implying massive upside. We continue to see ongoing rapid growth in the U.S., but do caution that a big economic slowdown could hurt government and commercial spending. All things considered, on the next drawdown we would be buyers.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir: Complete Disaster</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir: Complete Disaster\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-20 16:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4513287-palantir-complete-disaster><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>So, Palantir Technologies Inc. (NYSE:PLTR) stock has been a total disaster for longs. Many retail \"bag-holders\" out there. And we would like to point out that we were wrong in our last column on the ...</p>\n\n<a href=\"https://seekingalpha.com/article/4513287-palantir-complete-disaster\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://seekingalpha.com/article/4513287-palantir-complete-disaster","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2236030678","content_text":"So, Palantir Technologies Inc. (NYSE:PLTR) stock has been a total disaster for longs. Many retail \"bag-holders\" out there. And we would like to point out that we were wrong in our last column on the stock, despite making our members money. In our last column we predicted it would be emerging from the ashes and put out a profitable short-term trade recommendation in that piece. Winning.However, we were also wrong, because we thought the bottom was put in after it reset back to trade just about at its direct public offering price. We got that part wrong.While we get the win on the trade, we recognize that investors are getting creamed. Unfortunately this is a trader's market right now, and we have had a short bias the last few months, with selective long-term plays only in the most quality of names. We hate to see investors lose money, and we know it can be painful. The question is, what can we expect going forward. Is all hope lost here? We keep hearing that that technology stocks, especially those that are potential game-changing names, are on sale. But are they?Names like Palantir are indeed often extremely expensive in the early stages. You really cannot value them on an earnings basis because there are no or very little earnings. Palantir also has a massive dilution problem, which means consistent positive EPS gets kicked further down the road. We think Palantir has a lot of potential, but this market is beyond unforgiving to those companies that do not make money or have sky high valuations. It does not matter at all how much promise they have; the stocks are all down and down massively. What can you do? We think there are three possible courses of action in the disaster that has been Palantir, all of which are correct.The first option is the easiest, and perhaps a \"cop out\" for lack of a better term. But that option is to simply avoid the stock altogether in favor of deep value names offering some yield protection and are still managing to grow. We would not short down here at $7-$8, as the stock really has been pounded. The risk-reward is not favorable on a short after all of the action. So, you could do nothing and just watch it. If you own the stock, that would be a simple hold then. You could consider selling some upside calls on big bounces to lower cost basis if you choose.The second course of action is in our wheelhouse. And that is to trade the name. Right now, we think that $7 level is a buy for gains to be sold at $8-$9, maybe $10. But this market environment is not going to get any better for innovative tech in the near-term. You could then consider some put options or mild shorts if the stock does enjoy a sizable bounce from the oversold conditions.The third option is likely where a lot of readers are interested, and that is simply invest in the name, not obsess over the day-to-day tick in price. Add selectively to a well-rounded portfolio to improve cost basis, and put faith in management that it can deliver on growing the business profitably without diluting shareholders into oblivion. Right now this is a tall order for this company and management. While operationally the company is growing sufficiently, management has some credibility issues. What one has to do is determine if what the company offers will solve enough headaches for customers that eventually the growing sales turn into sustained and growing profits.For years, Palantir may lose money or breakeven. Of course, the theory goes that companies like this will lose money as they spend to attract customers and build their moat. They invest heavily in their growth while seeing revenues increase dramatically. And as we know, Palantir is seeing revenues grow tremendously.So, what is our take? We think you wait for the next down day in the stock. It has enjoyed a sizable relief bounce from the lows, but we believe the stock will retest these lows as the economy continues to worsen, rates are going up, and markets struggle. We would be both traders and investors at $7. The risk could be that Palantir's growth fades and the company never really transforms the world. New competitors could emerge. Dilution could continue so long that positive EPS becomes out of reach without future buybacks. We hate to say it but frankly, it is not uncommon for stocks in seemingly innovative companies to wither away to sub $1 then eventually delist because the company failed to grow and deliver on its plans.Although we were wrong in that bottom call, operationally we are seeing some positive signs. Internal metrics improve year-after-year for Palantir and we see no reason why the ongoing growth will not eventually lead to real profits, other than dilution. We admit and accept that so many great companies start out losing money. While the Russia/Ukraine conflict was a seemingly bullish development as it highlights a need to mine data for intelligence, some see a limited benefit for Palantir. For the long-term investor, we like a buy in this stock on weakness that sends the stock lower. While it will still be expensive, even for high growth tech, it will be much more reasonable compared to a few months ago. And it is not like the company is bleeding out and losing money hand over first. Palantir is breaking even and making some money some quarters.Palantir's Government and Commercial sectors showing growthIn the just reported quarter, performance was strong on the top line and ahead of consensus estimates. Total revenue grew 31% year-over-year to $446 million, beating estimates by almost $3 million. However, its profitability was lower than expected by $0.02, and worse, guidance was less than consensus. That crushed the stock. But that said, both segments are doing well.Palantir has two reporting segments: both the government and commercial segments. The commercial revenue stream continues to grow rapidly, while government results are likely to get a big boost following international strife. While the war in Ukraine may or may not lead to more business the company has invested in itself to grow sales. There are some concerns with backlog, but as we previously covered, Palantir has been hiring.Palantir has expanded its sales team and they have been working to secure new orders. However, the Government revenues have slowed their growth somewhat. Deceleration of revenue growth is definitely a negative for a company like this that does not enjoy high earnings. They rose 16% from last year, and the company added a total of 40 net new customers in the quarter, which is very positive, 3 on the government side and 37 on the commercial side. We think it is important to note that the commercial space is doing well. The commercial revenue is expanding rapidly, increasing 132% in 2021, and here in Q1, it rose 54% year-over-year.Palantir is seeing very positive momentum in its margins as well. Positive movement in margins is important in a software company as it really highlights strengths, or weaknesses, in the way it distributes its products. Palantir is delivering. Adjusted gross margin was 81%. Contribution margin was 57%. First quarter adjusted income from operations, excluding stock-based compensation and related employer payroll taxes was $117 million, representing an adjusted operating margin of 26%, ahead of management's prior guidance of 23%. This is positive.Palantir is slightly profitable, for nowDespite the pull back now to single-digits, the stock is actually still expensive, like so many other growth tech names. The company lost $39 million in the quarter operationally, but adjusted income from operations was $117 million. The company is still free cash flow positive. Adjusted free cash flow was $30 million for the quarter. That said, the company was profitable at a $0.02 adjusted EPS bottom line figure, but this missed estimated by $0.02, so that is a negative, and another reason the stock is down.We say the company is profitable for now for two reasons. First, there is a ton of stock based-compensation. This has been discussed in the past but we have to reiterate that we like that management has acknowledged that it is a problem. Still, it is ongoing, and every share that is issued waters down the ability to increase EPS. In short, shareholders could be diluted into losses. The second reason is that although there is growth internationally, as well as big gains in the U.S., we could see the government and companies slash spending if there is a recession. Each week, things seem to get worse in terms of how expensive things are, and corporate earnings reports continue to highlight the tremendous pressure inflation is putting on them. While Palantir's technology should help governments and businesses alike operate more efficiently, and therefore more profitably, we could see reduced spending on services like this.Still expensiveOn the valuation front, the stock is still pricey. Sure, looking at traditional price-to-earnings is futile, but if you did you would see a stock at like 50X. Very pricey. Perhaps the more appropriate measure is the price-to-sales ratio, but not only is this still very high, the market has basically said it is no longer willing to pay for sky high multiples. Keep that in mind. At 9X sales, the stock is much cheaper than it has ever been, but it is still not \"cheap\". We would highlight that the PEG ratio is reasonable and we like the cash flow metrics.The outlook is murkyThe biggest concern right now is not valuation. It is not dilution. It is not the \"overall market.\" The largest issue is a slowdown in performance. The Q2 guidance was pretty weak. The company perhaps is underpromising to overdeliver, by management guided to a base case of $470 million in revenue. This was below consensus of $484 million. However in the release management noted that \"there is a wide range of potential upside to [the] guidance.\" The one positive factor to highlight is that Palantir continues to see 30% annual revenue growth through 2025.Take homeThe company operates with no debt and has nice positive free cash flow. They are poised to benefit from strong secular trends in big data and using analytics to improve operations. In the short-term, it is painful. Long-term, minus the dilution issues, there is a lot of promise here for future profits. The customer growth is impressive as is the revenue growth. While the stock has been a disaster, man analysts have price targets implying massive upside. We continue to see ongoing rapid growth in the U.S., but do caution that a big economic slowdown could hurt government and commercial spending. All things considered, on the next drawdown we would be buyers.","news_type":1},"isVote":1,"tweetType":1,"viewCount":534,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":807702702,"gmtCreate":1628054881506,"gmtModify":1703500380345,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574328305423311","authorIdStr":"3574328305423311"},"themes":[],"htmlText":"Will the booster jab (3rd jab vaccination)&nbsp;boost the share ptocebof PFE ?","listText":"Will the booster jab (3rd jab vaccination)&nbsp;boost the share ptocebof PFE ?","text":"Will the booster jab (3rd jab vaccination) boost the share ptocebof PFE ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/807702702","repostId":"1156524625","repostType":4,"repost":{"id":"1156524625","kind":"news","pubTimestamp":1628053893,"share":"https://ttm.financial/m/news/1156524625?lang=&edition=fundamental","pubTime":"2021-08-04 13:11","market":"us","language":"en","title":"Pfizer hikes 2021 outlook after vaccine boosts sales, profit","url":"https://stock-news.laohu8.com/highlight/detail?id=1156524625","media":"Business Hala","summary":"Strong sales of its COVID-19 vaccine and other drugs helped Pfizer nearly double its second-quarter ","content":"<p>Strong sales of its COVID-19 vaccine and other drugs helped<b> <a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b> nearly double its second-quarter revenue and boost its profit by 59%, beating Wall Street’s expectations.</p>\n<p></p>\n<p>Strong sales of its COVID-19 vaccine and other drugs helped Pfizer nearly double its second-quarter revenue and boost its profit to 59%, beating Wall Street’s expectations and helping the drug giant look forward to 2021. Helped to rapidly increase sales and profit forecasts.</p>\n<p>Amid the growing coronavirus pandemic, the COVID-19 vaccine became Pfizer’s top seller, generating nearly half of its revenue — $7.84 billion from direct sales and revenue splitting with its partner, Germany’s BioNTech.</p>\n<p>Pfizer now forecasts revenue from the two-dose vaccine this year to reach $33.5 billion for the 2.1 billion doses it has been contracted to provide by the end of the year. This does not include the contract signed last week to provide an additional 200 million doses to the US</p>\n<p>The New York company revealed on Wednesday that an ongoing trial of a booster shot given six months after the second vaccine dose showed that it increased antibody levels against the more-transmissible delta variant to 11 times higher in older people and younger people. increased more than five times. , compared to levels after two doses. The company also released data showing that six months after vaccination, the shots were 97% effective at preventing serious disease.</p>\n<p>“We are absolutely convinced that a booster will be needed,” CEO Albert Boerla said in an interview, “that a third dose of the original vaccine may be sufficient.” Still, in August Pfizer will begin testing a booster targeting the Delta version in volunteers, because “there’s so much at stake, you can’t take the risk.”</p>\n<p>Bourla said Pfizer has delivered more than 1 billion doses of the vaccine globally and expects to make 3 billion doses this year, with many more going to low- and middle-income countries. So far, most of the doses of all COVID-19 vaccines produced in Europe and the US have gone to rich countries.</p>\n<p>By the end of September, trials in 5- to 11-year-old volunteers should produce the safety and efficacy data necessary to obtain emergency use authorization in that age group, and data on trials in children 6 months to 5 years of age should be used. must comply. Soon according to Pfizer.</p>\n<p>The US Food and Drug Administration is now reviewing data that could lead to full approval of the vaccine for adults, which Borla said could reduce hesitation from vaccination.</p>\n<p>Second-quarter net income was $5.56 billion, or 98 cents per share, up from $3.49 billion, or 62 cents per share.</p>\n<p>Adjusted earnings, excluding one-time gains and losses, amounted to $6.08 billion, or $1.07 per share, significantly higher than Wall Street’s 97 cents.</p>\n<p>Its quarterly revenue of $18.98 billion is up from last year’s $9.86 billion, and also topped estimates.</p>\n<p>Pfizer shares rose $1.46, or 3.5%, to $43.56, near a 52-week high.</p>\n<p>Sales of Pfizer’s drugs for cancer and rare diseases, as well as drugs primarily used in hospitals, grew double-digit. Sales of Eliquis for preventing blood clots and stroke rose 16% to $1.48 billion, while Ibrance’s sales rose 4% to $1.4 billion in the quarter.</p>\n<p>Pfizer’s pneumonia vaccine Prevnar 13 – the world’s most lucrative vaccine by far – climbed 11% in sales to $1.24 billion amid the pandemic. The company won US approval in June for Prevnar 20, an updated version for adults that protects against seven more strains of pneumococcal disease.</p>\n<p>In May, Pfizer and partner Myovent received approval for MyFembry to reduce heavy menstrual bleeding due to uterine fibroids in premenopausal women.</p>\n<p>Pfizer’s head of research Mikel Dolstein outlined eight major research programs with the potential to have a major impact on public health, including a pill to treat COVID-19 and vaccines against Lyme disease and respiratory syncytial virus, which occur each year. Infects and kills more than 5% of adults. about 15,000 of them in the US</p>\n<p>Pfizer now expects adjusted full-year earnings in the range of $3.95 to $4.05 per share, up from its May forecast of $3.55 to $3.65 per share, and revenue in the range of $78 billion to $80 billion. , from $70.5 billion to $72.5 billion.</p>\n<p></p>","source":"lsy1627951004805","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer hikes 2021 outlook after vaccine boosts sales, profit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer hikes 2021 outlook after vaccine boosts sales, profit\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-04 13:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://businesshala.com/pfizer-hikes-2021-outlook-after-vaccine-boosts-sales-profit/><strong>Business Hala</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Strong sales of its COVID-19 vaccine and other drugs helped Pfizer nearly double its second-quarter revenue and boost its profit by 59%, beating Wall Street’s expectations.\n\nStrong sales of its COVID-...</p>\n\n<a href=\"https://businesshala.com/pfizer-hikes-2021-outlook-after-vaccine-boosts-sales-profit/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://businesshala.com/pfizer-hikes-2021-outlook-after-vaccine-boosts-sales-profit/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1156524625","content_text":"Strong sales of its COVID-19 vaccine and other drugs helped Pfizer nearly double its second-quarter revenue and boost its profit by 59%, beating Wall Street’s expectations.\n\nStrong sales of its COVID-19 vaccine and other drugs helped Pfizer nearly double its second-quarter revenue and boost its profit to 59%, beating Wall Street’s expectations and helping the drug giant look forward to 2021. Helped to rapidly increase sales and profit forecasts.\nAmid the growing coronavirus pandemic, the COVID-19 vaccine became Pfizer’s top seller, generating nearly half of its revenue — $7.84 billion from direct sales and revenue splitting with its partner, Germany’s BioNTech.\nPfizer now forecasts revenue from the two-dose vaccine this year to reach $33.5 billion for the 2.1 billion doses it has been contracted to provide by the end of the year. This does not include the contract signed last week to provide an additional 200 million doses to the US\nThe New York company revealed on Wednesday that an ongoing trial of a booster shot given six months after the second vaccine dose showed that it increased antibody levels against the more-transmissible delta variant to 11 times higher in older people and younger people. increased more than five times. , compared to levels after two doses. The company also released data showing that six months after vaccination, the shots were 97% effective at preventing serious disease.\n“We are absolutely convinced that a booster will be needed,” CEO Albert Boerla said in an interview, “that a third dose of the original vaccine may be sufficient.” Still, in August Pfizer will begin testing a booster targeting the Delta version in volunteers, because “there’s so much at stake, you can’t take the risk.”\nBourla said Pfizer has delivered more than 1 billion doses of the vaccine globally and expects to make 3 billion doses this year, with many more going to low- and middle-income countries. So far, most of the doses of all COVID-19 vaccines produced in Europe and the US have gone to rich countries.\nBy the end of September, trials in 5- to 11-year-old volunteers should produce the safety and efficacy data necessary to obtain emergency use authorization in that age group, and data on trials in children 6 months to 5 years of age should be used. must comply. Soon according to Pfizer.\nThe US Food and Drug Administration is now reviewing data that could lead to full approval of the vaccine for adults, which Borla said could reduce hesitation from vaccination.\nSecond-quarter net income was $5.56 billion, or 98 cents per share, up from $3.49 billion, or 62 cents per share.\nAdjusted earnings, excluding one-time gains and losses, amounted to $6.08 billion, or $1.07 per share, significantly higher than Wall Street’s 97 cents.\nIts quarterly revenue of $18.98 billion is up from last year’s $9.86 billion, and also topped estimates.\nPfizer shares rose $1.46, or 3.5%, to $43.56, near a 52-week high.\nSales of Pfizer’s drugs for cancer and rare diseases, as well as drugs primarily used in hospitals, grew double-digit. Sales of Eliquis for preventing blood clots and stroke rose 16% to $1.48 billion, while Ibrance’s sales rose 4% to $1.4 billion in the quarter.\nPfizer’s pneumonia vaccine Prevnar 13 – the world’s most lucrative vaccine by far – climbed 11% in sales to $1.24 billion amid the pandemic. The company won US approval in June for Prevnar 20, an updated version for adults that protects against seven more strains of pneumococcal disease.\nIn May, Pfizer and partner Myovent received approval for MyFembry to reduce heavy menstrual bleeding due to uterine fibroids in premenopausal women.\nPfizer’s head of research Mikel Dolstein outlined eight major research programs with the potential to have a major impact on public health, including a pill to treat COVID-19 and vaccines against Lyme disease and respiratory syncytial virus, which occur each year. Infects and kills more than 5% of adults. about 15,000 of them in the US\nPfizer now expects adjusted full-year earnings in the range of $3.95 to $4.05 per share, up from its May forecast of $3.55 to $3.65 per share, and revenue in the range of $78 billion to $80 billion. , from $70.5 billion to $72.5 billion.","news_type":1},"isVote":1,"tweetType":1,"viewCount":765,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":807706941,"gmtCreate":1628054725583,"gmtModify":1703500377391,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574328305423311","authorIdStr":"3574328305423311"},"themes":[],"htmlText":"Turn to RED MOON now!","listText":"Turn to RED MOON now!","text":"Turn to RED MOON now!","images":[{"img":"https://static.tigerbbs.com/2ef0259d7e3fb071dde7bf5e6836d5ba","width":"1125","height":"2083"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/807706941","isVote":1,"tweetType":1,"viewCount":506,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":807700409,"gmtCreate":1628054431501,"gmtModify":1703500371024,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574328305423311","authorIdStr":"3574328305423311"},"themes":[],"htmlText":"Toyota! My trusted car","listText":"Toyota! My trusted car","text":"Toyota! My trusted car","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/807700409","repostId":"1136976094","repostType":4,"isVote":1,"tweetType":1,"viewCount":602,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":807477898,"gmtCreate":1628054319814,"gmtModify":1703500369870,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574328305423311","authorIdStr":"3574328305423311"},"themes":[],"htmlText":"Inari has good prospect! At 18x is a good bargain","listText":"Inari has good prospect! At 18x is a good bargain","text":"Inari has good prospect! At 18x is a good bargain","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/807477898","repostId":"1124757232","repostType":4,"repost":{"id":"1124757232","kind":"news","pubTimestamp":1628045612,"share":"https://ttm.financial/m/news/1124757232?lang=&edition=fundamental","pubTime":"2021-08-04 10:53","market":"us","language":"en","title":"3 COVID Stocks That Could Soar Higher","url":"https://stock-news.laohu8.com/highlight/detail?id=1124757232","media":"The Motley Fool","summary":"Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.\nKey Points\n\nPfi","content":"<p><b><i>Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.</i></b></p>\n<p><b>Key Points</b></p>\n<ul>\n <li>Pfizer might surprise to the upside.</li>\n <li>Inari Medical is growing like gangbusters.</li>\n <li>Novavax's vaccine might be an important booster shot as the COVID-19 virus mutates.</li>\n</ul>\n<p>COVID-19 and the international lockdown crashed the world economy in 2020. Many people have already been vaccinated and are looking forward to normalization. But COVID is mutating, and the new delta variant might toss a wrench into the world's reopening. How might investors protect themselves?</p>\n<p>A panel of Motley Fool contributors offers three ideas for healthcare stocks that will zoom higher in 2021, even if COVID takes a turn for the worse. Read more to see why you might want to buy shares of&nbsp;<b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b>,&nbsp;<b><a href=\"https://laohu8.com/S/NARI\">Inari Medical, Inc.</a></b>, and&nbsp;<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b>.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f3ed6a343e35e121aafbaa2b30134955\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<h3><b>Pfizer: More room to run</b></h3>\n<p><b>George Budwell</b>&nbsp;<b>(Pfizer):</b>&nbsp;American pharma titan Pfizer might not sound like a sexy pick among the present cohort of COVID vaccine players. Wall Street's current consensus has Comirnaty, the drugmaker's vaccine -- produced in partnership with&nbsp;<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;-- losing steam from a sales perspective starting in 2022.</p>\n<p>Because of the delta variant, however, Comirnaty's commercial life could turn out to be much longer than originally expected. And while the emergence of the highly transmissible variant is obviously terrible news for society at large, Pfizer and its shareholders are probably going to benefit from this unfortunate development.</p>\n<p>There are two clear reasons to think that Pfizer's stock could move higher on the delta issue. First and foremost, the company&nbsp;announced&nbsp;that an Emergency Use Authorization submission for a booster third shot might happen as soon as this month. Second, Pfizer plans to start clinical trials for a delta-specific version of the vaccine this month.</p>\n<p>Although the Food and Drug Administration and the Centers for Disease Control and Prevention have both recently downplayed the need for booster shots, Pfizer has already put forth a compelling case for a third jab in response to the rampant spread of the delta variant and the waning efficacy of Comirnaty 6 to 12 months following full vaccination.</p>\n<p>The big picture for investors is that Pfizer's 2022 revenue might jump by as much as 9.7% compared to 2021 -- that is, if a booster shot is indeed approved and the company also successfully develops a delta-specific vaccine. By contrast, Wall Street currently has the drugmaker's top line falling by 14.8% next year relative to 2021.</p>\n<p>Where is Pfizer's stock possibly headed? If all the pieces fall into place on the vaccine front, shares ought to command a $50 handle, from a conservative standpoint. That's roughly a 17% upswing from where the drugmaker's shares presently stand, and that's not even accounting for the company's attractive 3.64% dividend yield at current levels. Put simply, Pfizer's stock would only be trading at approximately 3.5 times 2022 sales if this scenario pans out, which is a rather modest valuation for a&nbsp;dividend-paying&nbsp;big pharma stock.</p>\n<h3><b>Inari Medical: Skyrocketing Sales</b></h3>\n<p><b>Patrick Bafuma</b>&nbsp;<b>(Inari Medical):</b>&nbsp;If you are looking for a stock with staying power after tailwinds from the pandemic subside, look to Inari Medical. There were 108,000 new COVID cases on July 27, 2021 -- the most since February 5, 2021, according to&nbsp;<i>The New York Times</i>&nbsp;-- and that number was up over eight times the seven-day average at the start of July. To make things even worse, COVID not only causes difficulty breathing but also more than triples a patient's risk of disabling and potentially life-threatening blood clots. And we're still not sure if being vaccinated fully mitigates the risk of blood clots when a patient has an asymptomatic or a mild COVID infection.</p>\n<p>This seems like a good setup for a commercial-stage med-tech company that has developed minimally invasive products designed to remove large blood clots without the need for powerful clot-busting drugs. Through the use of its ClotTriever and FlowTriever devices, Inari has treated over 25,000 patients so far. Clinicians performed approximately 5,500 procedures with the company's devices in the first quarter of 2021,&nbsp;up 130% from the same quarter last year&nbsp;and about 20% higher than the fourth quarter of 2020. With about 12% of admitted COVID patients developing blood clots, and about 35,000 COVID hospitalizations in the U.S. (and rising) as of July 27, according to<i>The Times</i>, Inari is likely to see an uptick in eligible cases.</p>\n<p>Not to mention the company's results thus far for blood clots in the lung are spectacular:</p>\n<ul>\n <li>With the historic 30-day mortality rate of intermediate and high-risk blood clots in the lungs at 9.7%, Inari's 0.4% 30-day mortality rate is impressive.</li>\n <li>There's a decreased 30-day readmission rate of 6.7% versus 24.4% with the usual care.</li>\n <li>Major adverse events within 48 hours occur at only a 1.3% rate.</li>\n <li>No ICU stays are required after the procedure.</li>\n</ul>\n<p>Add it all up, and Inari's retrieval device seems like an obvious choice.</p>\n<p>The company grew first-quarter revenue at 113% year over year, and&nbsp;18% sequentially, and had gross margins of 91.9% for the first quarter of 2021. So Inari's price-to-sales ratio of 18 makes it a growth stock on sale.</p>\n<p>Inari has&nbsp;less than 5% penetrationin the $3.8 billion U.S. market, and there's also lots of room to grow in Europe, where it launched earlier this year. That means there are plenty of opportunities for this $4.5-billion market cap company. While COVID has affected many elective and semi-elective procedures, it has clearly not slowed Inari, and it could even accelerate its uptake.</p>\n<h3><b>Novavax: How high can it go?</b></h3>\n<p><b>Taylor Carmichael</b>&nbsp;<b>(Novavax):</b>&nbsp;The vaccine&nbsp;biotech&nbsp;Novavax had an amazing 2020, with its share price running up&nbsp;2,700%&nbsp;on optimism for its COVID vaccine. While the company has yet to file for an Emergency Use Authorization, it expects to do so in this quarter. So far in 2021, the stock is up 60%.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0e7829d99a76c48579ba01c6e55fe14f\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>NVAX DATA BY YCHARTS.</span></p>\n<p>Positive phase 3 data for the COVID-19 vaccine sent the stock soaring early in the year, but the share price has come back down to earth as the company has suffered delays getting its vaccine to market. First there was a shortage of raw materials necessary to make the vaccine. Now the company has to prove that its various contract manufacturing facilities will keep the vaccine quality consistent across all the sites.</p>\n<p>Despite these delays, long-term investors have reasons to be bullish. Manufacturing is scaling up, with production rates expected to hit 100 million doses a month by the end of the third quarter, and 150 million doses a month by December. While many people in the U.S. have already been vaccinated, the opportunity in the rest of the world is sizable. Novavax has pre-sold 1.1 billion doses to COVAX (an international vaccine consortium), and has contracted to supply hundreds of millions of doses around the world.</p>\n<p>In the U.S., the Novavax vaccine might primarily be used as a&nbsp;booster shot&nbsp;for people who have already been vaccinated. \"They may be really the right ones for boosters,\" Dr. Luciana Borio, the acting chief scientist at the F.D.A. from 2015 to 2017, told&nbsp;<i>The New York Times</i>.</p>\n<p>Down the road, Novavax plans on combining its COVID vaccine with its flu vaccine, making aone-shot regimen. While COVID does not mutate as quickly as the flu, we've seen several mutating strains over the last year. It's likely that we will need to vaccinate more than once in the years ahead.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 COVID Stocks That Could Soar Higher</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 COVID Stocks That Could Soar Higher\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-04 10:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/03/3-covid-stocks-that-will-soar-higher/><strong>The Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.\nKey Points\n\nPfizer might surprise to the upside.\nInari Medical is growing like gangbusters.\nNovavax's vaccine might...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/03/3-covid-stocks-that-will-soar-higher/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NARI":"Inari Medical, Inc.","NVAX":"诺瓦瓦克斯医药","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/08/03/3-covid-stocks-that-will-soar-higher/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124757232","content_text":"Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.\nKey Points\n\nPfizer might surprise to the upside.\nInari Medical is growing like gangbusters.\nNovavax's vaccine might be an important booster shot as the COVID-19 virus mutates.\n\nCOVID-19 and the international lockdown crashed the world economy in 2020. Many people have already been vaccinated and are looking forward to normalization. But COVID is mutating, and the new delta variant might toss a wrench into the world's reopening. How might investors protect themselves?\nA panel of Motley Fool contributors offers three ideas for healthcare stocks that will zoom higher in 2021, even if COVID takes a turn for the worse. Read more to see why you might want to buy shares of Pfizer, Inari Medical, Inc., and Novavax.\nIMAGE SOURCE: GETTY IMAGES.\nPfizer: More room to run\nGeorge Budwell (Pfizer): American pharma titan Pfizer might not sound like a sexy pick among the present cohort of COVID vaccine players. Wall Street's current consensus has Comirnaty, the drugmaker's vaccine -- produced in partnership with BioNTech SE -- losing steam from a sales perspective starting in 2022.\nBecause of the delta variant, however, Comirnaty's commercial life could turn out to be much longer than originally expected. And while the emergence of the highly transmissible variant is obviously terrible news for society at large, Pfizer and its shareholders are probably going to benefit from this unfortunate development.\nThere are two clear reasons to think that Pfizer's stock could move higher on the delta issue. First and foremost, the company announced that an Emergency Use Authorization submission for a booster third shot might happen as soon as this month. Second, Pfizer plans to start clinical trials for a delta-specific version of the vaccine this month.\nAlthough the Food and Drug Administration and the Centers for Disease Control and Prevention have both recently downplayed the need for booster shots, Pfizer has already put forth a compelling case for a third jab in response to the rampant spread of the delta variant and the waning efficacy of Comirnaty 6 to 12 months following full vaccination.\nThe big picture for investors is that Pfizer's 2022 revenue might jump by as much as 9.7% compared to 2021 -- that is, if a booster shot is indeed approved and the company also successfully develops a delta-specific vaccine. By contrast, Wall Street currently has the drugmaker's top line falling by 14.8% next year relative to 2021.\nWhere is Pfizer's stock possibly headed? If all the pieces fall into place on the vaccine front, shares ought to command a $50 handle, from a conservative standpoint. That's roughly a 17% upswing from where the drugmaker's shares presently stand, and that's not even accounting for the company's attractive 3.64% dividend yield at current levels. Put simply, Pfizer's stock would only be trading at approximately 3.5 times 2022 sales if this scenario pans out, which is a rather modest valuation for a dividend-paying big pharma stock.\nInari Medical: Skyrocketing Sales\nPatrick Bafuma (Inari Medical): If you are looking for a stock with staying power after tailwinds from the pandemic subside, look to Inari Medical. There were 108,000 new COVID cases on July 27, 2021 -- the most since February 5, 2021, according to The New York Times -- and that number was up over eight times the seven-day average at the start of July. To make things even worse, COVID not only causes difficulty breathing but also more than triples a patient's risk of disabling and potentially life-threatening blood clots. And we're still not sure if being vaccinated fully mitigates the risk of blood clots when a patient has an asymptomatic or a mild COVID infection.\nThis seems like a good setup for a commercial-stage med-tech company that has developed minimally invasive products designed to remove large blood clots without the need for powerful clot-busting drugs. Through the use of its ClotTriever and FlowTriever devices, Inari has treated over 25,000 patients so far. Clinicians performed approximately 5,500 procedures with the company's devices in the first quarter of 2021, up 130% from the same quarter last year and about 20% higher than the fourth quarter of 2020. With about 12% of admitted COVID patients developing blood clots, and about 35,000 COVID hospitalizations in the U.S. (and rising) as of July 27, according toThe Times, Inari is likely to see an uptick in eligible cases.\nNot to mention the company's results thus far for blood clots in the lung are spectacular:\n\nWith the historic 30-day mortality rate of intermediate and high-risk blood clots in the lungs at 9.7%, Inari's 0.4% 30-day mortality rate is impressive.\nThere's a decreased 30-day readmission rate of 6.7% versus 24.4% with the usual care.\nMajor adverse events within 48 hours occur at only a 1.3% rate.\nNo ICU stays are required after the procedure.\n\nAdd it all up, and Inari's retrieval device seems like an obvious choice.\nThe company grew first-quarter revenue at 113% year over year, and 18% sequentially, and had gross margins of 91.9% for the first quarter of 2021. So Inari's price-to-sales ratio of 18 makes it a growth stock on sale.\nInari has less than 5% penetrationin the $3.8 billion U.S. market, and there's also lots of room to grow in Europe, where it launched earlier this year. That means there are plenty of opportunities for this $4.5-billion market cap company. While COVID has affected many elective and semi-elective procedures, it has clearly not slowed Inari, and it could even accelerate its uptake.\nNovavax: How high can it go?\nTaylor Carmichael (Novavax): The vaccine biotech Novavax had an amazing 2020, with its share price running up 2,700% on optimism for its COVID vaccine. While the company has yet to file for an Emergency Use Authorization, it expects to do so in this quarter. So far in 2021, the stock is up 60%.\nNVAX DATA BY YCHARTS.\nPositive phase 3 data for the COVID-19 vaccine sent the stock soaring early in the year, but the share price has come back down to earth as the company has suffered delays getting its vaccine to market. First there was a shortage of raw materials necessary to make the vaccine. Now the company has to prove that its various contract manufacturing facilities will keep the vaccine quality consistent across all the sites.\nDespite these delays, long-term investors have reasons to be bullish. Manufacturing is scaling up, with production rates expected to hit 100 million doses a month by the end of the third quarter, and 150 million doses a month by December. While many people in the U.S. have already been vaccinated, the opportunity in the rest of the world is sizable. Novavax has pre-sold 1.1 billion doses to COVAX (an international vaccine consortium), and has contracted to supply hundreds of millions of doses around the world.\nIn the U.S., the Novavax vaccine might primarily be used as a booster shot for people who have already been vaccinated. \"They may be really the right ones for boosters,\" Dr. Luciana Borio, the acting chief scientist at the F.D.A. from 2015 to 2017, told The New York Times.\nDown the road, Novavax plans on combining its COVID vaccine with its flu vaccine, making aone-shot regimen. While COVID does not mutate as quickly as the flu, we've seen several mutating strains over the last year. It's likely that we will need to vaccinate more than once in the years ahead.","news_type":1},"isVote":1,"tweetType":1,"viewCount":802,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":803293762,"gmtCreate":1627439678656,"gmtModify":1703489992445,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574328305423311","authorIdStr":"3574328305423311"},"themes":[],"htmlText":"Anyone drinking beers","listText":"Anyone drinking beers","text":"Anyone drinking beers","images":[{"img":"https://static.tigerbbs.com/2bfc4834d8c3e481cb02a247326c4a8f","width":"1125","height":"2793"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/803293762","isVote":1,"tweetType":1,"viewCount":429,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":809384115,"gmtCreate":1627348416737,"gmtModify":1703488044503,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574328305423311","authorIdStr":"3574328305423311"},"themes":[],"htmlText":"Nice beer, Samual Adam","listText":"Nice beer, Samual Adam","text":"Nice beer, Samual Adam","images":[{"img":"https://static.tigerbbs.com/8c81143c8d7d05e9c1d1bf9c10749ede","width":"1125","height":"2629"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/809384115","isVote":1,"tweetType":1,"viewCount":551,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":178477161,"gmtCreate":1626834797553,"gmtModify":1703766101583,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574328305423311","authorIdStr":"3574328305423311"},"themes":[],"htmlText":"???","listText":"???","text":"???","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/178477161","repostId":"2153761308","repostType":2,"repost":{"id":"2153761308","kind":"highlight","pubTimestamp":1626834023,"share":"https://ttm.financial/m/news/2153761308?lang=&edition=fundamental","pubTime":"2021-07-21 10:20","market":"hk","language":"zh","title":"奈雪的茶跌近4% 较招股价已跌超35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2153761308","media":"新浪港股","summary":"7月21日消息，奈雪的茶持续下跌，现跌3.82%，报13.08港元，最新市值224.34亿港元。\n　　奈雪的茶于6月30日首挂上市，每股定价19.8港元。上市当日破发，此后股价持续下行，今日再度跌近4%，低见12.86港元，较招股价已跌超35%。\n\n\n海量资讯、精准解读，尽在新浪财经APP","content":"<html><body><div>\n<div>\n<div>\n<img src=\"http://image.sinajs.cn/newchart/hk_stock/min_660/02150.gif\"/>\n</div>\n</div>\n<p>　　7月21日消息，<span><a href=\"https://laohu8.com/S/02150\">奈雪的茶</a></span><span></span>持续下跌，现跌3.82%，报13.08港元，最新市值224.34亿港元。</p>\n<p>　　奈雪的茶于6月30日首挂上市，每股定价19.8港元。上市当日破发，此后股价持续下行，今日再度跌近4%，低见12.86港元，较招股价已跌超35%。</p>\n<div>\n<div><img src=\"\"/></div>\n<div>海量资讯、精准解读，尽在<a href=\"https://laohu8.com/S/SINA\">新浪</a>财经APP</div>\n</div>\n</div></body></html>","source":"highlight_sina","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>奈雪的茶跌近4% 较招股价已跌超35%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n奈雪的茶跌近4% 较招股价已跌超35%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-21 10:20 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/hkstock/marketalerts/2021-07-21/doc-ikqciyzk6703448.shtml><strong>新浪港股</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>7月21日消息，奈雪的茶持续下跌，现跌3.82%，报13.08港元，最新市值224.34亿港元。\n　　奈雪的茶于6月30日首挂上市，每股定价19.8港元。上市当日破发，此后股价持续下行，今日再度跌近4%，低见12.86港元，较招股价已跌超35%。\n\n\n海量资讯、精准解读，尽在新浪财经APP</p>\n\n<a href=\"https://finance.sina.com.cn/stock/hkstock/marketalerts/2021-07-21/doc-ikqciyzk6703448.shtml\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/67b872f6d508e7d70db55d570f1b762b","relate_stocks":{"02150":"奈雪的茶"},"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2021-07-21/doc-ikqciyzk6703448.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","article_id":"2153761308","content_text":"7月21日消息，奈雪的茶持续下跌，现跌3.82%，报13.08港元，最新市值224.34亿港元。\n　　奈雪的茶于6月30日首挂上市，每股定价19.8港元。上市当日破发，此后股价持续下行，今日再度跌近4%，低见12.86港元，较招股价已跌超35%。\n\n\n海量资讯、精准解读，尽在新浪财经APP","news_type":1},"isVote":1,"tweetType":1,"viewCount":871,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":178473966,"gmtCreate":1626834447955,"gmtModify":1703766092504,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574328305423311","authorIdStr":"3574328305423311"},"themes":[],"htmlText":"What about Nio; Xpeng Lucid etc etc ?","listText":"What about Nio; Xpeng Lucid etc etc ?","text":"What about Nio; Xpeng Lucid etc etc ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/178473966","repostId":"1110113604","repostType":4,"isVote":1,"tweetType":1,"viewCount":566,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"following","isTTM":true}